About WAMA Labs
WAMA Labsí methods and technology featuring issues/research in the scientific forefront, often in collaboration with a clinical psychiatrist, are well documented in several publications from internationally distinguished scientific journals
Wadenberg M-L et al.(1998) A novel computer controlled conditioned avoidance apparatus for rats. J Pharmacol & Toxicol Methods 38:211-215.
Wadenberg M-L et al.(2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 150:422-429.
Wadenberg M-L et al.(2001) Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25: 633-641.
Wadenberg M-L (1996) Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci and Biobehav Reviews 20:325-339.
Wadenberg M-L and Hicks P B (1999) The conditioned avoidance response test re-evaluated: Is it a sensitive test also for the detection of potentially atypical antipsychotics? Neurosci and Biobehav Reviews 23:851-862.
Wadenberg M-L G (2010) Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Design 16:358-370.
Birrell JM and Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set-shifting in the rat. The J Neurosci 20:4320-4324
Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiat 148:1301-1308.
Jentsch JD and Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacol 20:201-225
Currently going on
Head of WAMA Labs, Dr Marie-Louise Wadenberg is a former Recipient of an Investigator Award from the International Congress of Schizophrenia Research (ICOSR) organization. At a recent ICOSR-meeting (that also invited former Award Recipients to a reunion) in Orlando Florida, Dr Wadenberg presented data on the effects of the Alzheimer drug galantamine (alone and in the presence of low dose antipsychotic risperidone) in the attentional set-shifting test for cognitive functions.
In September, Dr Wadenberg is invited to present experimental data with cholinergic acting drugs, using tests for antipsychotic activity as well as cognitive functioning, at a meeting in Copenhagen, Denmark featuring several prominent speakers from USA, UK, Italy, Germany, Australia and Denmark.